NEW YORK — Proteomics firm Nomic Bio said Tuesday that it has closed a $42 million Series B funding round, led by an unnamed US-based investor with participation from firms including Amplitude Ventures, Avant Bio, Lux Capital, Real Ventures, and SR One.
The Montreal-based company said it will use the funds to expand its commercial operations and advance its nELISA protein profiling platform.
Based on technology developed in the lab of David Juncker, a professor of biomedical engineering at McGill University, nELISA uses a miniaturized, bead-based ELISA format to multiplex hundreds to thousands of immunoassays rapidly and without the problem of antibody cross-reactivity.
According to Nomic, the company has more than 75 customers for its platform including a number of large pharma and biotech firms. Collectively, these customers have run more than 400,000 samples on the platform.
The Series B round follows a $17 million Series A funding round the company closed in 2021.
"Nomic was founded to help scientific teams succeed in their mission to extend health spans," Milad Dagher, the company’s CEO and cofounder, said in a statement. "We’re excited to see our technology embraced by some of the most innovative R&D teams and to witness the nELISA platform advance critical drug discovery efforts. As we set out to greatly increase our biological footprint alongside unlocking several new applications, we are energized to partner with a distinguished group of investors who share our bold vision."